Not all patients require this dose
In addition to these approved uses, clinical trials in people with specific health conditions have shown that GLP-1s offer additional benefits, such as: Reducing the risk of heart attack and stroke Slowing kidney disease progression Treating moderate-to-advanced liver fibrosis Treating moderate-to-severe obstructive sleep apnea Also, semaglutide (Wegovy) is FDA-approved for chronic weight management in adolescents age 12 and older with obesity
They can be modified to be longer-lasting, to hit particular receptors, or to minimize side effects
It is expected that tirzepatide will occupy a greater percentage of GIPR than GLP1R (4.1, 4.6, and 6.3 fold, respectively, at 15, 10, and 5 mg) [16]
Collaborative decision-making with your healthcare team ensures optimal outcomes for both metabolic and sexual health